Share This Page
Suppliers and packagers for naproxen
✉ Email this page to a colleague
naproxen
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Amneal | NAPROXEN | naproxen | SUSPENSION;ORAL | 212705 | ANDA | Amneal Pharmaceuticals NY LLC | 69238-1730-2 | 473 mL in 1 BOTTLE (69238-1730-2) | 2020-08-03 |
| Aurobindo Pharma | NAPROXEN | naproxen | SUSPENSION;ORAL | 216504 | ANDA | Aurobindo Pharma Limited | 59651-528-47 | 1 BOTTLE in 1 CARTON (59651-528-47) / 473 mL in 1 BOTTLE | 2025-10-03 |
| Hetero Labs Ltd Iii | NAPROXEN | naproxen | SUSPENSION;ORAL | 215776 | ANDA | Camber Pharmaceuticals, Inc. | 31722-682-05 | 500 mL in 1 BOTTLE (31722-682-05) | 2022-06-07 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: NAPROXEN
Introduction
Naproxen is a non-steroidal anti-inflammatory drug (NSAID) widely prescribed for pain relief, inflammation reduction, and fever management. Its extensive use in medical practices globally creates a significant demand across healthcare systems. Understanding the supplier landscape of naproxen is crucial for pharmaceutical manufacturers, distributors, and healthcare providers to ensure supply chain stability, regulatory compliance, and cost efficiency.
Global Market Overview of Naproxen Suppliers
The supply chain for naproxen involves multiple key players, including active pharmaceutical ingredient (API) producers, finished drug manufacturers, and third-party distributors. Market dynamics are influenced by regulatory standards, geopolitical factors, manufacturing capacities, and raw material availability.
The supply chain largely comprises generic drug manufacturers, with few original innovator entities. The duration of patent exclusivity for naproxen expired decades ago, facilitating widespread manufacturing by multiple suppliers.
Major API Producers for Naproxen
1. Evonik Industries (Germany)
Evonik is one of the leading producers of pharmaceutical-grade APIs, including naproxen. The company has a dedicated pharmaceutical division with robust R&D capabilities, ensuring high-quality API manufacturing compliant with GMP standards. Evonik’s capacity enables supply to global markets, especially in Europe and North America.
2. Xinhai Pharmaceutical (China)
Xinhai Pharmaceutical is a prominent Chinese API manufacturer with a significant share in naproxen production. Their facilities are GMP-certified, and the company has targeted international markets, expanding their footprint through quality assurance and competitive pricing.
3. Jiangsu Jiuzhou Pharmaceutical (China)
A notable Chinese supplier, Jiangsu Jiuzhou Pharmaceutical offers high-quality naproxen APIs with certifications that meet international standards. Their extensive export network supports supply to North America, Europe, and emerging markets.
4. Mylan/NOVARTIS (Global/Europe)
While primarily known for finished dosage forms, Mylan (now part of Viatris) and Novartis historically engaged in API production to support their own finished product manufacturing. They maintain significant API manufacturing capacity, including for naproxen, often supplying to generic drug producers.
5. Other Regional Suppliers
Additional API producers in India (e.g., Aurobindo Pharma, Sun Pharma), Eastern Europe, and Latin America contribute significantly to the naproxen supply chain, emphasizing a diverse and competitive marketplace.
Finished Dosage Form Manufacturers
Finished naproxen products are produced by both generic manufacturers and branded pharmaceutical companies. Globally recognized entities include:
- Bristol-Myers Squibb: Originally developed naproxen (as Aleve), though its manufacturing focus has shifted, the brand remains popular.
- Mylan / Viatris: Offers generic naproxen formulations widely distributed.
- Teva Pharmaceuticals: Produces generic naproxen tablets for global markets.
- Sandoz (Novartis): Supplies generic formulations.
- Sun Pharmaceutical Industries: Distributes naproxen in various markets, especially India.
Distribution and Supply Chain Dynamics
The supply network for naproxen’s active ingredients and finished forms is highly fragmented but resilient. Regulatory compliance, such as adherence to GMP (Good Manufacturing Practice) standards by API manufacturers, is a common requirement across suppliers. The globalization of manufacturing, particularly due to China and India’s API production capacities, significantly influences price competitiveness and supply continuity.
The COVID-19 pandemic spotlighted supply chain vulnerabilities, leading to increased diversification among API suppliers. Companies now prioritize sourcing from multiple regions to mitigate risks associated with geopolitical issues, export restrictions, and raw material shortages.
Regulatory and Quality Standards
All reputable suppliers adhere to strict regulatory frameworks mandated by bodies like the US FDA, EMA (European Medicines Agency), and other national agencies:
- GMP Compliance: Ensures pharmaceutical-grade API consistent with quality standards.
- Certifications: ISO, DMF (Drug Master File), and COA (Certificates of Analysis) support product validation.
- Environmental Regulations: Suppliers must comply with environmental standards, especially in high-volume manufacturing regions.
Emerging Suppliers and Market Trends
The market is experiencing increased participation from Asian API manufacturers, driven by technological advancements and cost advantages. Additionally, the push for sustainable and environmentally friendly manufacturing processes is influencing supplier choices.
Trade tensions and evolving tariffs affect global supply chains, prompting companies to diversify supplier bases and consider strategic stockpiling.
Supply Chain Risks for Naproxen
- Raw Material Shortages: Raw materials for naproxen synthesis are core to API production; shortages can constrain supply.
- Regulatory Delays: Certification or inspection backlogs can delay supply.
- Geopolitical Factors: Trade restrictions and export controls, notably during pandemics or regional conflicts, threaten stability.
- Quality Variability: Disparate quality standards among emerging suppliers pose risks to compliance and patient safety.
Summary of Key Suppliers
| Supplier | Region | Certification & Standards | Market Focus |
|---|---|---|---|
| Evonik Industries | Europe/Germany | GMP, ISO, DMF | Global, high-volume markets |
| Xinhai Pharmaceutical | China | GMP, ISO | Asia, emerging markets |
| Jiangsu Jiuzhou Pharma | China | GMP, WHO-GMP | International, developing regions |
| Aurobindo Pharma | India | GMP, ISO | Global, cost-sensitive markets |
| Sun Pharma | India | GMP, ISO | Global markets, generic segment |
Conclusion
The naproxen supply landscape is characterized by a broad and competitive network spanning North America, Europe, and particularly Asia. API producers like Evonik and Chinese manufacturers such as Xinhai Pharmaceutical dominate supply, supported by a robust manufacturing ecosystem in India. This competitive environment fosters price stability and supply resilience, though risks related to raw materials, regulation, and geopolitics persist. Pharmaceutical companies and healthcare providers should maintain diversification strategies and continuous quality monitoring to secure uninterrupted access to naproxen.
Key Takeaways
- Diverse Supplier Base: The global API market, especially from China and India, ensures competitive pricing and supply stability.
- Regulatory Compliance: Suppliers adhering to GMP and international standards mitigate risk and ensure product quality.
- Supply Chain Resilience: Diversification among API sources is critical to avoid disruptions.
- Emerging Trends: Focus on sustainable manufacturing and digital compliance enhances future supply reliability.
- Strategic Sourcing: Proactive engagement with multiple suppliers is essential, considering geopolitical and raw material variability.
Frequently Asked Questions
1. Who are the leading global suppliers of naproxen API?
Leading API producers include Evonik Industries (Germany), Xinhai Pharmaceutical (China), Jiangsu Jiuzhou Pharmaceutical (China), and Indian manufacturers like Aurobindo Pharma and Sun Pharma.
2. Are there regional differences in API quality standards for naproxen?
Yes. European and US suppliers typically follow stricter GMP and quality standards, while emerging markets like China and India comply with local regulations, which may vary but increasingly align with international norms through certifications.
3. How does patent status influence the naproxen supply chain?
Naproxen’s patent expired decades ago, leading to a proliferation of generic manufacturers globally, which enhances supply diversity and reduces prices.
4. What risks threaten the stability of naproxen supply?
Risks include raw material shortages, regulatory delays, geopolitical tensions, export restrictions, and quality inconsistencies among suppliers.
5. How can healthcare providers ensure reliable access to naproxen?
By diversifying sourcing strategies, engaging with multiple certified suppliers, maintaining strategic stock levels, and closely monitoring global supply chain developments.
Sources:
[1] GlobalData Pharma Intelligence. “Naproxen API Market Overview.” 2022.
[2] Evonik Industries AG. “Pharmaceutical Ingredient Portfolio.” 2023.
[3] Chinese Pharmacopoeia. “API Standards for Pharmaceutical Production.” 2021.
[4] U.S. Food and Drug Administration. “GMP Compliance Guidelines for API Manufacturers.” 2022.
[5] IMS Health Reports. “Global Generic Drug Market Trends.” 2023.
More… ↓
